Unichem laboratories buyback
Unichem Laboratories touched their 52-week high, gaining 6.65 per cent, the companies will consider unichem laboratories buyback of equity shares on January 8, 2018.Unichem Laboratories board meeting will also be held on January 8, 2018 to consider a proposal for buyback of fully paid-up equity shares of the company. The company will also consider and approve the audited results for the period ended December 31, 2017.
Unichem Laboratories is one of India’s oldest and largest pharmaceutical company headquartered in Mumbai, Maharashtra, India. Unichem has plants located in Roha (Maharashtra), Goa, Baddi (Himachal Pradesh), Pithampur, Ghaziabad, & Sikkim. The company has made more than 500 product registrations across the world and more than 500 regulatory filings such as DMFs, EDMFs. It has been granted Certificate of suitability to European Pharmacopeia (CEP) by European Directorate for the Quality of Medicines and Healthcare (EDQM) for Alfuzosin Hydrochloride. Company main interest in synthesis, development, manufacturing, marketing and export of bulk drugs, chemical intermediates and formulations, serving the needs of both human and veterinary health-care,Unichem has several pharma products that address the needs of relevant and growing therapeutic areas like gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterials, anti-infectives and pain management.
Unichem laboratories founded in 1944, Mumbai . Mr. Amrut mody is Founder of the company . Unichem company served in world wide in pharmaceuticals market,
key people of this unichem laboratories
- MD & Chairman , Dr. P A Mody
- CEO, Mr. Bhagwat S Dhingra.
Revenue of Unichem laboratories 6,971.8 Million
Profit of Unichem laboratories is 1,339.3 Million
Number of Employees in Unichem laboratories is 4700.
Subsidiries of Unichem laboratories
- Niche Generics, UK
- Unichem SA (Pty) Ltd
- Unichem Farmaceutica do Brasil Ltd
- Unichem Pharmaceuticals (USA)
The Company has taken several important strides in the critical area of Research and Development (R&D). It has expanded its R&D facility in Goa to spearhead research in Novel Drug Delivery Systems (NDDS) and chemically synthesize non-infringing routes for the manufacture of medical products directed at regulated markets. In its effort to drive innovation, Unichem has established a proprietary formulation development centre in Goa to focus on the development of generic formulations comprising Immediate Release as well as NDDS and ANDAs exclusively for the US market. The facility has also been equipped to handle the development of formulations for New Chemical Entities (NCEs). Further, the company has also established a biotech facility at Goa to invent, design, develop and commercialise biotech and biosimilar products.
Unichem Laboratories BUYBACK
Buyback No.of Shares: 2.06 Cr.
Buyback Size: Rs. 885.80 Cr.
Buyback Price: Rs.430/share
CMP: Rs.360 /share
Small Shareholder Reservation holding up to 465 Qty: 30.9 lacs shares
Expected Acceptance upto 465 Qty- 90%-100% (Small Shareholders Category)
Holding Period: 3-4 months
Annualised Return 58-60%.
OLDER POSTS –